第九届董事会第一次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 联化科技股份有限公司（以下简称"公司"）第九届董事会第一次会议通知 于2025年9月11日以电子邮件方式通知各董事（包括董事候选人）。会议于2025 年9月16日在联化科技会议室以现场与通讯表决相结合的方式召开。会议应出席 董事7人，实际出席董事7人。公司高级管理人员列席了本次会议，与会董事一致 推荐王萍女士主持会议，符合《公司法》、《证券法》等法律法规、部门规章、规 范性文件及《公司章程》的有关规定。会议形成如下决议： 一、会议以7票同意，0票反对，0票弃权的表决结果，审议并通过了《关于 选举董事长的议案》。 与会董事一致选举王萍女士为公司第九届董事会董事长，其任期自本次董事 会审议通过之日起至第九届董事会届满为止。 二、会议以7票同意，0票反对，0票弃权的表决结果，审议并通过了《关于 选举代表公司执行公司事务董事的议案》。 与会董事一致选举王萍女士为公司第九届董事会代表公司执行公司事务董 事，其任期自本次董事会审议通过之日起至第九届董事会届满为止。 三、会议以7票同意，0票反对 ...

Company Overview - Lianhua Technology Co., Ltd. is located in Taizhou, Zhejiang Province, established on September 14, 1998, and listed on June 19, 2008 [2] - The company operates in three main business segments: pesticides, pharmaceuticals, and functional chemicals, with revenue contributions of 54.03%, 32.32%, 8.42%, and 4.88% from equipment and engineering services, respectively [2] - As of June 30, 2025, the number of shareholders increased by 88.92% to 72,300, while the average circulating shares per person decreased by 47.07% to 12,533 shares [2] Financial Performance - For the first half of 2025, Lianhua Technology achieved a revenue of 3.15 billion yuan, representing a year-on-year growth of 5.76%, and a net profit attributable to shareholders of 224 million yuan, a significant increase of 1481.94% [2] - The company has distributed a total of 960 million yuan in dividends since its A-share listing, with 129 million yuan distributed over the past three years [3] Stock Market Activity - On September 16, Lianhua Technology's stock price fell by 2.03% to 11.12 yuan per share, with a trading volume of 182 million yuan and a turnover rate of 1.79%, resulting in a total market capitalization of 10.134 billion yuan [1] - Year-to-date, the stock price has increased by 102.55%, but it has seen a decline of 1.77% over the last five trading days and a drop of 17.38% over the past 60 days [1] - The company has appeared on the "Dragon and Tiger List" nine times this year, with the most recent appearance on June 25, where it recorded a net buy of -46.854 million yuan [1]

Core Viewpoint - Jinhua New Materials (920015.BJ) has initiated its subscription on September 16, with an issue price of 18.15 CNY per share and a maximum subscription limit of 1.5516 million shares, reflecting a price-to-earnings ratio of 11.52 times. The company specializes in the research, production, and sales of ketoxime series fine chemicals, with applications across various industries including construction materials, energy, electronics, new energy vehicles, pesticides, pharmaceuticals, metal extraction agents, ion exchange resins, and environmentally friendly dyes [1]. Company Overview - Jinhua New Materials focuses on the development of silane crosslinking agents, hydroxylamine salts, methoxyamine hydrochloride, and acetaldehyde oxime, which are essential for producing organic silicon sealants and adhesives, widely used in strategic emerging industries [1][2]. - The company has established stable partnerships with multinational corporations such as Bayer and Braskem, as well as listed companies like Wanhua Chemical and Xin'an Chemical [2]. Market Position - The domestic market share of Jinhua New Materials for silane crosslinking agents is projected to increase from 27.85% in 2022 to 38.16% in 2024. For hydroxylamine salts, the market share is expected to shift from 34.86% in 2022 to 42.37% in 2024 [2]. Financial Performance - The company reported revenues of approximately 994 million CNY, 1.115 billion CNY, and 1.239 billion CNY for the years 2022, 2023, and 2024, respectively. Net profits for the same years were approximately 79.59 million CNY, 173 million CNY, and 211 million CNY [3][4]. - Total assets are projected to grow from approximately 859.68 million CNY in 2022 to 1.322 billion CNY in 2024, with total equity increasing from approximately 477.59 million CNY to 842.66 million CNY over the same period [4]. Investment Projects - The net proceeds from the current issuance will be allocated to several projects, including a high-end coupling agent project with an investment of approximately 50.69 million CNY, a pilot project with an investment of approximately 2.3 million CNY, and an intelligent factory construction project for the ketoxime industry chain with an investment of approximately 6.31 million CNY [3]. Profitability Metrics - The gross profit margin is expected to improve from 17.72% in 2022 to 27.94% in 2024. The net profit margin is projected to increase from 8.01% in 2022 to 17.00% in 2024 [5]. - The company’s basic earnings per share are forecasted to rise from 0.8291 CNY in 2022 to 2.1525 CNY in 2024 [5].

Core Viewpoint - Jinhua New Materials (920015.BJ) has initiated its subscription with an issue price of 18.15 CNY per share and a price-to-earnings ratio of 11.52, focusing on the development, production, and sales of ketoxime series fine chemicals, with significant applications across various industries [1][2]. Group 1: Company Overview - Jinhua New Materials specializes in ketoxime series fine chemicals, including silane crosslinking agents, hydroxylamine salts, methoxyamine hydrochloride, and acetaldehyde oxime, which are used in construction materials, energy, electronics, new energy vehicles, pesticides, pharmaceuticals, metal extractants, ion exchange resins, and environmentally friendly dyes [1]. - The company's silane crosslinking agents are key raw materials for producing silicone sealants and adhesives, widely used in strategic emerging industries, particularly in new materials [1][2]. Group 2: Market Position and Growth - The domestic market share of Jinhua New Materials for silane crosslinking agents is projected to increase from 27.85% in 2022 to 38.16% in 2024, while the market share for hydroxylamine salts is expected to rise from 34.86% in 2022 to 42.37% in 2024 [2]. - The company has established stable partnerships with major multinational corporations such as Bayer and Braskem, as well as listed companies like Wanhua Chemical and Xinan Co., Ltd. [2]. Group 3: Financial Performance - Jinhua New Materials reported revenues of approximately 994 million CNY in 2022, 1.115 billion CNY in 2023, and projected 1.239 billion CNY in 2024, with net profits of 79.59 million CNY, 173 million CNY, and 211 million CNY respectively [3][4]. - The total assets of the company increased from approximately 859.68 million CNY in 2022 to about 1.322 billion CNY in 2024, with total equity rising from 477.59 million CNY to 842.66 million CNY during the same period [4]. - The gross profit margin improved from 17.72% in 2022 to 27.94% in 2024, indicating enhanced profitability [5].

Group 1 - The company, Lianhua Technology, has formed strategic partnerships with leading manufacturers in both domestic and international markets [1] - The company leverages its technical expertise and production resources to provide differentiated and customized product services to clients [1] - The company aims to grow alongside its clients by developing and offering a variety of competitive key chemicals [1]

Core Viewpoint - The company is actively focusing on the development of cutting-edge products in the new energy sector, aligning with customer demands and optimizing its services and technology to reduce costs and promote innovation [1] Group 1 - The company is responding to customer needs in its new energy business [1] - The company is committed to product planning and service optimization [1] - The company aims to lower costs and foster innovation for future growth [1]

Core Viewpoint - The company, Lianhua Technology (002250), is focusing on its pharmaceutical business primarily through a CDMO (Contract Development and Manufacturing Organization) model and aims to actively expand its business to ensure continuous development [1] Summary by Relevant Sections - **Company Business Model** - The pharmaceutical business of the company is mainly based on the CDMO model [1] - **Business Development Strategy** - The company will actively engage in business development efforts to promote sustained growth [1]

了解本次路演交流，请点击：https://ir.p5w.net/c/920015.shtml 浙江锦华新材料股份有限公司向不特定合格投资者公开发行股票并在北交所上市网上路演于2025年9月 15日（星期一）14:00-16:00在全景路演举行。 路演现场，锦华新材董事会秘书李晓晨表示，公司已与拜耳（Bayer）、布伦泰格（Brenntag）等大型 跨国企业及万华化学（600309.SH）、新安股份（600596.SH）、先达股份（603086.SH）、联化科技 （002250.SZ）、湖南海利（600731.SH）等上市公司建立稳定的合作关系；此外，硅宝科技 （300019.SZ）、富乐（FUL.N）、集泰股份（002909.SZ）、回天新材（300041.SZ）、东方雨虹 （002271.SZ）、蓝晓科技（300487.SZ）、赛恩斯（688480.SH）、康普化学（834033.BJ）等国内外上 市公司均为公司主要的终端客户。 ...

Company Overview - Lianhua Technology Co., Ltd. is located in Taizhou, Zhejiang Province, established on September 14, 1998, and listed on June 19, 2008 [2] - The company operates in three main sectors: pesticides, pharmaceuticals, and functional chemicals, with revenue contributions of 54.03%, 32.32%, 8.42%, and 4.88% from equipment and engineering services, respectively [2] - As of June 30, the number of shareholders increased to 72,300, with an average of 12,533 circulating shares per person, a decrease of 47.07% [2] Financial Performance - For the first half of 2025, Lianhua Technology achieved revenue of 3.15 billion yuan, a year-on-year increase of 5.76%, and a net profit attributable to shareholders of 224 million yuan, a significant increase of 1481.94% [2] - The company has distributed a total of 960 million yuan in dividends since its A-share listing, with 129 million yuan distributed in the last three years [3] Stock Performance - On September 15, Lianhua Technology's stock price rose by 2.13% to 11.52 yuan per share, with a trading volume of 407 million yuan and a turnover rate of 3.98%, bringing the total market capitalization to 10.499 billion yuan [1] - The stock has increased by 109.84% year-to-date, with a slight increase of 0.44% over the last five trading days and a 12.94% increase over the last 20 days, while it has decreased by 10.90% over the last 60 days [1] - The company has appeared on the trading leaderboard nine times this year, with the most recent appearance on June 25, where it recorded a net buy of -46.85 million yuan [1] Shareholding Structure - As of June 30, the second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 40.3583 million shares, an increase of 21.3384 million shares from the previous period [3] - The fund "Noan Pioneer Mixed A" has exited the list of the top ten circulating shareholders [3]

Group 1 - The company is experiencing a gradual recovery in its plant protection business [2] - An investor inquired about the sufficiency of the company's plant protection business orders for the second half of the year [2] - The company responded positively regarding the current state of its plant protection business [2]